Vasopressin V1a and V1b receptors: from molecules to physiological systems.

The neurohypophysial hormone arginine vasopressin (AVP) is essential for a wide range of physiological functions, including water reabsorption, cardiovascular homeostasis, hormone secretion, and social behavior. These and other actions of AVP are mediated by at least three distinct receptor subtypes: V1a, V1b, and V2. Although the antidiuretic action of AVP and V2 receptor in renal distal tubules and collecting ducts is relatively well understood, recent years have seen an increasing understanding of the physiological roles of V1a and V1b receptors. The V1a receptor is originally found in the vascular smooth muscle and the V1b receptor in the anterior pituitary. Deletion of V1a or V1b receptor genes in mice revealed that the contributions of these receptors extend far beyond cardiovascular or hormone-secreting functions. Together with extensively developed pharmacological tools, genetically altered rodent models have advanced the understanding of a variety of AVP systems. Our report reviews the findings in this important field by covering a wide range of research, from the molecular physiology of V1a and V1b receptors to studies on whole animals, including gene knockout/knockdown studies.

[1]  Maurice Manning,et al.  Probing the Existence of G Protein-Coupled Receptor Dimers by Positive and Negative Ligand-Dependent Cooperative Binding , 2006, Molecular Pharmacology.

[2]  G. Tsujimoto,et al.  Alcohol preference in mice lacking the Avpr1a vasopressin receptor. , 2008, American journal of physiology. Regulatory, integrative and comparative physiology.

[3]  A. Tanoue,et al.  Altered lipid metabolism in vasopressin V1B receptor-deficient mice. , 2009, European journal of pharmacology.

[4]  Morton Jj,et al.  Vasopressin and hypertension in man. , 1986 .

[5]  I. Nabi,et al.  Association of calnexin with wild type and mutant AVPR2 that causes nephrogenic diabetes insipidus. , 2001, Biochemistry.

[6]  S. Patel,et al.  Critical role of a subdomain of the N-terminus of the V1a vasopressin receptor for binding agonists but not antagonists; functional rescue by the oxytocin receptor N-terminus. , 2000, Biochemistry.

[7]  G. Guillon,et al.  Vasopressin : a potent autocrine/paracrine regulator of mammal adrenal functions. , 1998, Endocrine research.

[8]  K. Kovács,et al.  Effects of repeated restraint stress on hypothalamo-pituitary-adrenocortical function in vasopressin deficient Brattleboro rats , 2004, Brain Research Bulletin.

[9]  J. Schafer,et al.  Regulation of Na+ channels in the cortical collecting duct by AVP and mineralocorticoids. , 1992, Kidney international.

[10]  W. Young,et al.  Expression of vasopressin V1a and V2 receptor messenger ribonucleic acid in the liver and kidney of embryonic, developing, and adult rats. , 1993, Endocrinology.

[11]  C. Camerino Low Sympathetic Tone and Obese Phenotype in Oxytocin‐deficient Mice , 2009, Obesity.

[12]  G. Tsujimoto,et al.  Impaired social interaction and reduced anxiety-related behavior in vasopressin V1a receptor knockout mice , 2007, Behavioural Brain Research.

[13]  M. Thibonnier,et al.  Role of the human V1 vasopressin receptor COOH terminus in internalization and mitogenic signal transduction. , 2001, American journal of physiology. Endocrinology and metabolism.

[14]  S. Hansson,et al.  Reproductive hormones in plasma over the menstrual cycle in primary dysmenorrhea compared with healthy subjects , 2008, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[15]  Desmopressin normalizes the blunted adrenocorticotropin response to corticotropin-releasing hormone in melancholic depression: evidence of enhanced vasopressinergic responsivity. , 1999, The Journal of clinical endocrinology and metabolism.

[16]  K. Nakao,et al.  Effects of the neurohypophysial hormones on insulin secretion. , 1967, Endocrinology.

[17]  E. D. de Kloet,et al.  Neurohypophyseal hormone receptors in the rat thymus, spleen, and lymphocytes. , 1990, Endocrinology.

[18]  A single residue (arg46) located within the N-terminus of the V1a vasopressin receptor is critical for binding vasopressin but not peptide or nonpeptide antagonists. , 2002, Molecular endocrinology.

[19]  W. Waldhäusl,et al.  Insulin production rate, hepatic insulin retention and splanchnic carbohydrate metabolism after oral glucose ingestion in hyperinsulinaemic Type 2 (non-insulin-dependent) diabetes mellitus , 1982, Diabetologia.

[20]  V. Locatelli,et al.  Central nervous system-acting drugs influencing hypothalamic-pituitary-adrenal axis function. , 2010, Endocrine development.

[21]  V. Gross,et al.  Control of renal medullary blood flow by vasopressin V1 and V2 receptors. , 1995, The American journal of physiology.

[22]  D. Cook,et al.  The effects of vasopressin on acute kidney injury in septic shock , 2009, Intensive Care Medicine.

[23]  D. Yule,et al.  Vasopressin directly closes ATP‐sensitive potassium channels evoking membrane depolarization and an increase in the free intracellular Ca2+ concentration in insulin‐secreting cells. , 1989, The EMBO journal.

[24]  E. Tribollet,et al.  Binding of the Non-Peptide Vasopressin V1a Receptor Antagonist SR-49059 in the Rat Brain: An in vitro and in vivo Autoradiographic Study , 1999, Neuroendocrinology.

[25]  S. Tufik,et al.  Suppression of Adrenocorticotrophic Hormone Secretion by Simultaneous Antagonism of Vasopressin 1b and CRH-1 Receptors on Three Different Stress Models , 2007, Neuroendocrinology.

[26]  M. Westphal,et al.  Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study , 2009 .

[27]  E. Frank,et al.  The vasopressin system--from antidiuresis to psychopathology. , 2008, European journal of pharmacology.

[28]  B. Bohus,et al.  Inhibition of centrally-evoked pressor responses by neurohypophyseal peptides and their fragments , 1982, Neuropharmacology.

[29]  Andrew H. Bass,et al.  Social behavior functions and related anatomical characteristics of vasotocin/vasopressin systems in vertebrates , 2001, Brain Research Reviews.

[30]  F. Leri,et al.  Involvement of Arginine Vasopressin and V1b Receptor in Heroin Withdrawal and Heroin Seeking Precipitated by Stress and by Heroin , 2008, Neuropsychopharmacology.

[31]  E. T. Segura,et al.  Repeated (isolation) stress increases tribulin-like activity in the rat , 1989, Cellular and Molecular Neurobiology.

[32]  R. Landgraf,et al.  Advances in vasopressin and oxytocin : from genes to behaviour to disease , 2008 .

[33]  S. Yibchok-anun,et al.  Effects of arginine vasopressin and oxytocin on glucagon release from clonal alpha-cell line In-R1-G9: involvement of V1b receptors. , 1998, Life sciences.

[34]  C. Auzan,et al.  Mechanisms of Cell-surface Rerouting of an Endoplasmic Reticulum-retained Mutant of the Vasopressin V1b/V3 Receptor by a Pharmacological Chaperone* , 2005, Journal of Biological Chemistry.

[35]  W. Mason,et al.  INOSITOL PHOSPHOLIPID TURNOVER AND INTRACELLULAR Ca2+ RESPONSES TO THYROTROPHIN‐RELEASING HORMONE, GONADOTROPHIN‐RELEASING HORMONE AND ARGININE VASOPRESSIN IN PITUITARY CORTICOTROPH AND SOMATOTROPH ADENOMAS , 1990, Clinical endocrinology.

[36]  N. Bucher,et al.  Internalization, recycling, and redistribution of vasopressin receptors in rat hepatocytes. , 1985, Journal of Biological Chemistry.

[37]  H. Schaff,et al.  Arginine vasopressin induces endothelium-dependent vasodilatation of the pulmonary artery. V1-receptor-mediated production of nitric oxide. , 1993, Chest.

[38]  J. Han,et al.  Vasopressin and oxytocin receptors coupled to Ca2+ mobilization in rat inner medullary collecting duct. , 1993, The American journal of physiology.

[39]  T. Kawada,et al.  Oxytocin receptor-deficient mice developed late-onset obesity , 2008, Neuroreport.

[40]  David L. Braff,et al.  Information-processing deficits and thought disorder in schizophrenia. , 1994 .

[41]  S. Yibchok-anun,et al.  Glucose dependency of arginine vasopressin-induced insulin and glucagon release from the perfused rat pancreas. , 2002, Metabolism: clinical and experimental.

[42]  K. Alberti,et al.  THE EFFECT OF VASOPRESSIN INFUSION ON GLUCOSE METABOLISM IN MAN , 1985, Clinical endocrinology.

[43]  M. Potegal,et al.  Vasopressin receptor blockade in the anterior hypothalamus suppresses aggression in hamsters , 1988, Physiology & Behavior.

[44]  V. Boulay,et al.  Design, synthesis, and pharmacological characterization of fluorescent peptides for imaging human V1b vasopressin or oxytocin receptors. , 2011, Journal of medicinal chemistry.

[45]  L. Young,et al.  Association of vasopressin 1a receptor levels with a regulatory microsatellite and behavior , 2005, Genes, brain, and behavior.

[46]  D. Gewirtz,et al.  Induction of Taurocholate Release from Isolated Rat Hepatocytes in Suspension by α‐Adrenergie Agents and Vasopressin: Implications for Control of Bile Salt Secretion , 1984, Hepatology.

[47]  D F Swaab,et al.  Gene expression analysis in the human hypothalamus in depression by laser microdissection and real-time PCR: the presence of multiple receptor imbalances , 2008, Molecular Psychiatry.

[48]  J. Liard L-NAME antagonizes vasopressin V2-induced vasodilatation in dogs. , 1994, The American journal of physiology.

[49]  J. Szmydynger-Chodobska,et al.  Multiple Sites of Vasopressin Synthesis in the Injured Brain , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[50]  J. Brobeck,et al.  Evidence for a Role of the Supraopticohypophyseal System in Regulation of Adrenocorticotropic Secretion , 1954, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[51]  R. Hodgson,et al.  Comparison of the V1b antagonist, SSR149415, and the CRF1 antagonist, CP-154,526, in rodent models of anxiety and depression , 2007, Pharmacology Biochemistry and Behavior.

[52]  M. Thibonnier,et al.  Dynamic interaction of human vasopressin/oxytocin receptor subtypes with G protein-coupled receptor kinases and protein kinase C after agonist stimulation. , 2000, The Journal of biological chemistry.

[53]  D. Feifel,et al.  The Brattleboro Rat Displays a Natural Deficit in Social Discrimination that is Restored by Clozapine and a Neurotensin Analogue , 2009, Neuropsychopharmacology.

[54]  H. Albers,et al.  Effect of photoperiod on vasopressin-induced aggression in Syrian hamsters , 2004, Hormones and Behavior.

[55]  J W Funder,et al.  Studies of the secretion of corticotropin-releasing factor and arginine vasopressin into the hypophysial-portal circulation of the conscious sheep. I. Effect of an audiovisual stimulus and insulin-induced hypoglycemia. , 1989, Neuroendocrinology.

[56]  E. Braunwald,et al.  The pressor effect of the antidiuretic principle of the posterior pituitary in orthostatic hypotension. , 1956, The Journal of clinical investigation.

[57]  Rachel A. Millstein,et al.  The acute intoxicating effects of ethanol are not dependent on the vasopressin 1a or 1b receptors , 2006, Neuropeptides.

[58]  D. Murphy,et al.  What's wrong with my mouse model? Advances and strategies in animal modeling of anxiety and depression , 2007, Behavioural Brain Research.

[59]  J. Hilton,et al.  Effect of synthetic lysine vasopressin on adrenocortical secretion. , 1959, Science.

[60]  K. Fuxe,et al.  Dimer-based model for heptaspanning membrane receptors. , 2005, Trends in biochemical sciences.

[61]  F. Holsboer,et al.  Selective activation of the hypothalamic vasopressinergic system in mice deficient for the corticotropin-releasing hormone receptor 1 is dependent on glucocorticoids. , 2000, Endocrinology.

[62]  K. Tomita,et al.  Regulation of V2R transcription by hypertonicity and V1aR-V2R signal interaction. , 2008, American journal of physiology. Renal physiology.

[63]  A. Meyer-Lindenberg,et al.  Genetic variants in AVPR1A linked to autism predict amygdala activation and personality traits in healthy humans , 2009, Molecular Psychiatry.

[64]  A. Kjaer,et al.  Impaired histamine- and stress-induced secretion of ACTH and beta-endorphin in vasopressin-deficient Brattleboro rats. , 1993, Neuroendocrinology.

[65]  Hyagriv N. Simhan,et al.  Prevention of Preterm Delivery , 2007 .

[66]  Kaori Sato,et al.  V2 Receptor–Mediated Autocrine Role of Somatodendritic Release of AVP in Rat Vasopressin Neurons Under Hypo-Osmotic Conditions , 2011, Science Signaling.

[67]  D. Rockey,et al.  Terlipressin in acute oesophageal variceal haemorrhage , 2003, Alimentary pharmacology & therapeutics.

[68]  A. Green,et al.  Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist , 2005, British journal of pharmacology.

[69]  J. Granton,et al.  Science Review: Vasopressin and the cardiovascular system part 2 – clinical physiology , 2003, Critical care.

[70]  M. Koch,et al.  Deficient Sensorimotor Gating After 6‐Hydroxydopamine Lesion of the Rat medial Prefrontal Cortex is Reversed by Haloperidol , 1994, The European journal of neuroscience.

[71]  J. Simms,et al.  The N-terminal juxtamembrane segment of the V1a vasopressin receptor provides two independent epitopes required for high-affinity agonist binding and signaling. , 2005, Molecular endocrinology.

[72]  R. Lamont,et al.  The choice of a tocolytic for the treatment of preterm labor: a critical evaluation of nifedipine versus atosiban , 2007, Expert opinion on investigational drugs.

[73]  K. Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2000, Science.

[74]  D. Hems,et al.  Stimulation by vasopressin of glycogen breakdown and gluconeogenesis in the perfused rat liver. , 1973, The Biochemical journal.

[75]  G. Guillon,et al.  Vasopressin receptors in human adrenal medulla and pheochromocytoma. , 1999, The Journal of clinical endocrinology and metabolism.

[76]  Larry J. Young,et al.  The V1a Vasopressin Receptor Is Necessary and Sufficient for Normal Social Recognition: A Gene Replacement Study , 2005, Neuron.

[77]  M. Åkerlund,et al.  Effects of SR 49059, an orally active V1a vasopressin receptor antagonist, on vasopressin‐induced uterine contractions , 1997, British journal of obstetrics and gynaecology.

[78]  L. Bankir,et al.  Vasopressin-V2 receptor stimulation reduces sodium excretion in healthy humans. , 2005, Journal of the American Society of Nephrology : JASN.

[79]  M. Goldman,et al.  Neonatal lesions of the ventral hippocampal formation disrupt neuroendocrine responses to auditory stress in the adult rat , 2004, Psychoneuroendocrinology.

[80]  R. Brouard,et al.  Safety, tolerability, and pharmacokinetics of SR 49059, a V1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers. , 1998, Advances in experimental medicine and biology.

[81]  John H. Zhang,et al.  Arginine-vasopressin V1a receptor inhibition improves neurologic outcomes following an intracerebral hemorrhagic brain injury , 2011, Neurochemistry International.

[82]  J. Burbach,et al.  Immunohistochemical localization of the vasopressin V1b receptor in the rat brain and pituitary gland: anatomical support for its involvement in the central effects of vasopressin. , 2001, Endocrinology.

[83]  M. Obinata,et al.  Aldosterone requires vasopressin V1a receptors on intercalated cells to mediate acid-base homeostasis. , 2011, Journal of the American Society of Nephrology : JASN.

[84]  J. R. Mcneill,et al.  Pressor Responsiveness and Cardiovascular Reflex Activity in Spontaneously Hypertensive and Normotensive Rats During Vasopressin Infusion , 1981, Journal of cardiovascular pharmacology.

[85]  K. Föhr,et al.  Oxytocin at physiological concentrations evokes adrenocorticotropin (ACTH) release from corticotrophs by increasing intracellular free calcium mobilized mainly from intracellular stores. Oxytocin displays synergistic or additive effects on ACTH-releasing factor or arginine vasopressin-induced ACTH s , 1992, Endocrinology.

[86]  K. Tomita,et al.  Vasopressin regulates the renin-angiotensin-aldosterone system via V1a receptors in macula densa cells. , 2008, American journal of physiology. Renal physiology.

[87]  J. R. Mcneill,et al.  Vasopressin accelerates protein synthesis in neonatal rat cardiomyocytes , 1999, Molecular and Cellular Biochemistry.

[88]  D. Wied,et al.  Central Nervous System Effects of the Neurohypophyseal Hormones and Related Peptides , 1993, Frontiers in Neuroendocrinology.

[89]  J. Vincent,et al.  Physiology and pathophysiology of the vasopressinergic system. , 2008, Best practice & research. Clinical anaesthesiology.

[90]  D. Swaab,et al.  Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. , 1996, Archives of general psychiatry.

[91]  J. Montastruc,et al.  EFFECTS OF LYSINE‐VASOPRESSIN AND OXYTOCIN ON CENTRAL CARDIOVASCULAR CONTROL , 1982, British journal of pharmacology.

[92]  C. Péqueux,et al.  Provasopressin expression by breast cancer cells: implications for growth and novel treatment strategies , 2006, Breast Cancer Research and Treatment.

[93]  M. Raggenbass Overview of cellular electrophysiological actions of vasopressin. , 2008, European journal of pharmacology.

[94]  Eric Trinquet,et al.  Cell surface detection of membrane protein interaction with homogeneous time-resolved fluorescence resonance energy transfer technology. , 2004, Analytical biochemistry.

[95]  Marc Leone Terlipressin or Europressin? , 2009, Critical care.

[96]  K. Tabei,et al.  Luminal vasopressin modulates transport in the rabbit cortical collecting duct. , 1991, The Journal of clinical investigation.

[97]  Q. Cai,et al.  Axial heterogeneity of vasopressin-receptor subtypes along the human and mouse collecting duct. , 2007, American journal of physiology. Renal physiology.

[98]  K. Momose,et al.  Both V(1A) and V(1B) vasopressin receptors deficiency result in impaired glucose tolerance. , 2009, European journal of pharmacology.

[99]  Peter Kirsch,et al.  Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine , 2011, Nature Reviews Neuroscience.

[100]  T. Sugimoto,et al.  Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor. , 1994, The Journal of biological chemistry.

[101]  J. Coyle,et al.  Glutamatergic mechanisms in schizophrenia. , 2003, Annual review of pharmacology and toxicology.

[102]  H. Vaudry,et al.  The pituitary V3 vasopressin receptor and the corticotroph phenotype in ectopic ACTH syndrome. , 1996, The Journal of clinical investigation.

[103]  T. Jovin,et al.  FRET imaging , 2003, Nature Biotechnology.

[104]  Graeme Milligan,et al.  Allostery at G Protein-Coupled Receptor Homo- and Heteromers: Uncharted Pharmacological Landscapes , 2010, Pharmacological Reviews.

[105]  P. Sawchenko,et al.  Reflex control of magnocellular vasopressin and oxytocin secretion , 1991, Trends in Neurosciences.

[106]  M. Brownstein,et al.  Molecular cloning and expression of a rat Via arginine vasopressin receptor , 1992, Nature.

[107]  H. Sadeghi,et al.  Phosphorylation and recycling kinetics of G protein-coupled receptors. , 1999, Journal of receptor and signal transduction research.

[108]  Charged Extracellular Residues, Conserved throughout a G-protein-coupled Receptor Family, Are Required for Ligand Binding, Receptor Activation, and Cell-surface Expression* , 2006, Journal of Biological Chemistry.

[109]  P. Robinson,et al.  The biosynthesis and secretion of adrenocorticotropin by the ovine anterior pituitary is predominantly regulated by arginine vasopressin (AVP). Evidence that protein kinase C mediates the action of AVP. , 1990, The Journal of biological chemistry.

[110]  R. Álvarez-Buylla,et al.  Arginine-vasopressin mediates central and peripheral glucose regulation in response to carotid body receptor stimulation with Na-cyanide. , 2006, Journal of applied physiology.

[111]  R. Lemmens‐Gruber,et al.  Vasopressin antagonists , 2006, Cellular and Molecular Life Sciences.

[112]  B. J. Barber,et al.  Vasopressin vascular and reflex effects--a theoretical analysis. , 1983, Progress in brain research.

[113]  B. Bannwarth,et al.  Placental transfer of SR49059 in the human dually perfused cotyledon in vitro. , 2001, Placenta.

[114]  Graeme Milligan,et al.  G-protein-coupled receptor heterodimers: pharmacology, function and relevance to drug discovery. , 2006, Drug discovery today.

[115]  D. Swaab,et al.  Increased Arginine Vasopressin mRNA Expression in the Human Hypothalamus in Depression: A Preliminary Report , 2006, Biological Psychiatry.

[116]  V. Wenzel,et al.  San Antonio Vasopressin in Shock Symposium report. , 2010, Resuscitation.

[117]  G. Kerkhof,et al.  Plasma arginine vasopressin and motor activity in major depression , 1998, Biological Psychiatry.

[118]  J. Buckingham UNDERSTANDING THE ROLE OF VASOPRESSIN IN THE HYPOTHALAMO-PITUITARY ADRENOCORTICAL AXIS , 2009 .

[119]  T. Sharma,et al.  Effects of typical and atypical antipsychotics on prepulse inhibition in schizophrenia: a critical evaluation of current evidence and directions for future research , 2002, Psychopharmacology.

[120]  A. Sanyal,et al.  A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. , 2008, Gastroenterology.

[121]  W. Young,et al.  Cloning of rat ARHGAP4/C1, a RhoGAP family member expressed in the nervous system that colocalizes with the Golgi complex and microtubules. , 2002, Brain research. Molecular brain research.

[122]  H. Vaudry,et al.  Identification of Amino Acid Residues That Direct Differential Ligand Selectivity of Mammalian and Nonmammalian V1a Type Receptors for Arginine Vasopressin and Vasotocin , 2004, Journal of Biological Chemistry.

[123]  R. Jankord,et al.  The stimuli-specific role of vasopressin in the hypothalamus-pituitary-adrenal axis response to stress. , 2009, The Journal of endocrinology.

[124]  R. Landgraf,et al.  An intrinsic vasopressin system in the olfactory bulb is involved in social recognition , 2010, Nature.

[125]  G. Griebel,et al.  Evidence that the Lateral Septum is Involved in the Antidepressant-Like Effects of the Vasopressin V1b Receptor Antagonist, SSR149415 , 2005, Neuropsychopharmacology.

[126]  H. D. Wardener The Hypothalamus and Hypertension , 2001 .

[127]  I. Pávó,et al.  Vasopressin pressor receptor-mediated activation of HPA axis by acute ethanol stress in rats. , 2001, American journal of physiology. Regulatory, integrative and comparative physiology.

[128]  G. Tsujimoto,et al.  Vasopressin stimulates insulin release from islet cells through V1b receptors: a combined pharmacological/knockout approach. , 2004, Molecular pharmacology.

[129]  Jan Born,et al.  Sniffing neuropeptides: a transnasal approach to the human brain , 2002, Nature Neuroscience.

[130]  R. Manchester,et al.  A radio pulsar with an 8.5-second period that challenges emission models , 1999, Nature.

[131]  C. Johnston,et al.  Restoration of Suppressed Baroreflex Sensitivity in Rats with Hereditary Diabetes Insipidus (Brattleboro Rats) by Arginine‐Vasopressin and DDAVP , 1983, Circulation research.

[132]  L. Bankir,et al.  Vasopressin V2 receptors, ENaC, and sodium reabsorption: a risk factor for hypertension? , 2010, American journal of physiology. Renal physiology.

[133]  J. R. Henderson,et al.  Immunohistochemical localization of oxytocin and vasopressin in the adrenal glands of rat, cow, hamster and guinea pig , 1987, Cell and Tissue Research.

[134]  H. Sadeghi,et al.  Arrestin effects on internalization of vasopressin receptors. , 2001, Molecular pharmacology.

[135]  E. Schäfer,et al.  On the Physiological Action of Extracts of Pituitary Body and certain other Glandular Organs , 1895 .

[136]  R. Bataller,et al.  Arginine vasopressin induces contraction and stimulates growth of cultured human hepatic stellate cells. , 1997, Gastroenterology.

[137]  K. Groom Pharmacological prevention of prematurity , 2007 .

[138]  W. Wilkison,et al.  The agouti gene product inhibits lipolysis in human adipocytes via a Ca2+‐dependent mechanism , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[139]  S. Angers,et al.  Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. , 2000, The Journal of clinical investigation.

[140]  K. Catt,et al.  Mechanisms of action of corticotropin-releasing factor and other regulators of corticotropin release in rat pituitary cells. , 1983, The Journal of biological chemistry.

[141]  G. Tsujimoto,et al.  Disruption of the Prepulse Inhibition of the Startle Reflex in Vasopressin V1b Receptor Knockout Mice: Reversal by Antipsychotic Drugs , 2005, Neuropsychopharmacology.

[142]  K. Catt,et al.  Mechanisms of Action of CRF and Other Regulators of ACTH Release in Pituitary Corticotrophs , 1987, Annals of the New York Academy of Sciences.

[143]  A. Marmarou,et al.  The modulation of aquaporin-4 by using PKC-activator (phorbol myristate acetate) and V1a receptor antagonist (SR49059) following middle cerebral artery occlusion/reperfusion in the rat. , 2008, Acta neurochirurgica. Supplement.

[144]  T. Suda,et al.  Lysine vasopressin stimulation of cortisol secretion in patients with adrenocorticotropin-independent macronodular adrenal hyperplasia. , 1995, The Journal of clinical endocrinology and metabolism.

[145]  R. Landgraf,et al.  Microdialysis administration of vasopressin into the septum improves social recognition in Brattleboro rats , 1994, Physiology & Behavior.

[146]  Kyung-sup Kim,et al.  Obese Gene Expression Alters the Ability of 30A5 Preadipocytes to Respond to Lipogenic Hormones* , 1996, The Journal of Biological Chemistry.

[147]  Didier Rognan,et al.  Identification of the Binding Sites of the SR49059 Nonpeptide Antagonist into the V1a Vasopressin Receptor Using Sulfydryl-reactive Ligands and Cysteine Mutants as Chemical Sensors* , 2003, Journal of Biological Chemistry.

[148]  J. Buckingham,et al.  Effects of naloxone on hypothalamo-pituitary-adrenocortical activity in the rat. , 1986, Neuroendocrinology.

[149]  G. Griebel,et al.  Blockade of CRF1 or V1b receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression , 2004, Molecular Psychiatry.

[150]  J. Genescà,et al.  Acute esophageal variceal bleeding: Current strategies and new perspectives. , 2010, World journal of hepatology.

[151]  J. Maffrand,et al.  Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. , 2002, Progress in brain research.

[152]  C. S. Gal,et al.  Pro-inflammatory role of vasopressin through V 1 b receptors in hapten-1 induced experimental colitis in rodents : implication in IBD 2 3 4 Running head : Vasopressin in experimental colitis 5 6 7 , 2010 .

[153]  M. Schambelan,et al.  Amelioration of metabolic acidosis with fludrocortisone therapy in hyporeninemic hypoaldosteronism. , 1977, The New England journal of medicine.

[154]  F. László,et al.  Pharmacology and clinical perspectives of vasopressin antagonists. , 1991, Pharmacological reviews.

[155]  W. Young,et al.  The role of the arginine vasopressin Avp1b receptor in the acute neuroendocrine action of antidepressants , 2008, Psychoneuroendocrinology.

[156]  S. Orr,et al.  Sex-specific influences of vasopressin on human social communication , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[157]  G. Tsujimoto,et al.  Attenuated stress-induced catecholamine release in mice lacking the vasopressin V1b receptor. , 2006, American journal of physiology. Endocrinology and metabolism.

[158]  P. Vaitkevicius,et al.  Therapeutic Potential of Vasopressin Receptor Antagonists , 2012, Drugs.

[159]  W. Young,et al.  Pituitary‐Adrenal Response to Acute and Repeated Mild Restraint, Forced Swim and Change in Environment Stress in Arginine Vasopressin Receptor 1b Knockout Mice , 2008, Journal of neuroendocrinology.

[160]  A. Diedrich,et al.  Vasopressin and blood pressure in humans. , 2000, Hypertension.

[161]  Zoe R. Donaldson,et al.  Central vasopressin V1a receptor activation is independently necessary for both partner preference formation and expression in socially monogamous male prairie voles. , 2010, Behavioral neuroscience.

[162]  F. Antoni Vasopressinergic Control of Pituitary Adrenocorticotropin Secretion Comes of Age , 1993, Frontiers in Neuroendocrinology.

[163]  尾上 尚志 Endothelium-dependent and -independent responses to vasodilators of isolated dog cerebral arteries , 1989 .

[164]  G. Tsujimoto,et al.  Decreased susceptibility to salt-induced hypertension in subtotally nephrectomized mice lacking the vasopressin V1a receptor. , 2010, Cardiovascular research.

[165]  M. Vaughan EFFECT OF PITRESSIN ON LIPOLYSIS AND ON PHOSPHORYLASE ACTIVITY IN RAT ADIPOSE TISSUE. , 1964, The American journal of physiology.

[166]  H. Sadeghi,et al.  A serine cluster prevents recycling of the V2 vasopressin receptor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[167]  N. Swerdlow,et al.  Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review , 2001, Psychopharmacology.

[168]  G. Howell,et al.  Vasopressin potentiates corticotropin-releasing hormone-induced insulin release from mouse pancreatic β-cells , 2008, The Journal of endocrinology.

[169]  F. Antoni,et al.  Hypothalamic control of adrenocorticotropin secretion: advances since the discovery of 41-residue corticotropin-releasing factor. , 1986, Endocrine reviews.

[170]  N. Cotte,et al.  Conserved aromatic residues in the transmembrane region VI of the V1a vasopressin receptor differentiate agonist vs. antagonist ligand binding. , 2000, European journal of biochemistry.

[171]  O. Boss,et al.  Direct effects of leptin on brown and white adipose tissue. , 1997, The Journal of clinical investigation.

[172]  R. Unger,et al.  Novel Form of Lipolysis Induced by Leptin* , 1999, The Journal of Biological Chemistry.

[173]  Patrick J. Coles,et al.  The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists. , 2001, Annual review of pharmacology and toxicology.

[174]  G. Nussdorfer Paracrine control of adrenal cortical function by medullary chromaffin cells. , 1996, Pharmacological reviews.

[175]  M. Palkovits,et al.  The vasopressin 1b receptor is prominent in the hippocampal area CA2 where it is unaffected by restraint stress or adrenalectomy , 2006, Neuroscience.

[176]  Qiang-sun Zheng,et al.  Effects of Arginine Vasopressin on Growth of Rat Cardiac Fibroblasts: Role of V1 Receptor , 2003, Journal of cardiovascular pharmacology.

[177]  V. Geenen,et al.  Oxytocin- and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway. , 2004, Endocrine-related cancer.

[178]  G. Guillon,et al.  Pharmacological characterization of F‐180: a selective human V1a vasopressin receptor agonist of high affinity , 2002, British journal of pharmacology.

[179]  J. Schafer Abnormal regulation of ENaC: syndromes of salt retention and salt wasting by the collecting duct. , 2002, American journal of physiology. Renal physiology.

[180]  C. Duijn,et al.  A major SNP haplotype of the arginine vasopressin 1B receptor protects against recurrent major depression , 2003, Molecular Psychiatry.

[181]  R. Chesnut,et al.  Open-Label Randomized Trial of the Safety and Efficacy of a Single Dose Conivaptan to Raise Serum Sodium in Patients with Traumatic Brain Injury , 2011, Neurocritical care.

[182]  J. Brown,et al.  Blood pressure in acute and chronic vasopressin excess: studies of malignant hypertension and the syndrome of inappropriate antidiuretic hormone secretion. , 1981, The New England journal of medicine.

[183]  H. Albers,et al.  Role of V1a vasopressin receptors in the control of aggression in Syrian hamsters , 2006, Brain Research.

[184]  R. Ebstein,et al.  Association between a vasopressin receptor AVPR1A promoter region microsatellite and eating behavior measured by a self-report questionnaire (Eating Attitudes Test) in a family-based study of a nonclinical population. , 2004, The International journal of eating disorders.

[185]  G. Gessa,et al.  Involvement of arginine vasopressin and V1b receptor in alcohol drinking in Sardinian alcohol-preferring rats. , 2011, Alcoholism, clinical and experimental research.

[186]  N. Kasting,et al.  Convulsive and hypothermic effects of vasopressin in the brain of the rat. , 1980, Canadian journal of physiology and pharmacology.

[187]  A. Yamanaka,et al.  Vasopressin Increases Locomotion through a V1a Receptor in Orexin/Hypocretin Neurons: Implications for Water Homeostasis , 2008, The Journal of Neuroscience.

[188]  D. Bichet Nephrogenic diabetes insipidus. , 1994, Advances in chronic kidney disease.

[189]  E. Hasser,et al.  Area Postrema And Sympathetic Nervous System Effects Of Vasopressin And Angiotensin II , 2000, Clinical and experimental pharmacology & physiology.

[190]  G. Tsujimoto,et al.  V1a receptor knockout mice exhibit impairment of spatial memory in an eight-arm radial maze , 2004, Neuroscience Letters.

[191]  Misao Suzuki,et al.  A Tubule Cell Line Established from Transgenic Mice Harboring Temperature‐sensitive Simian Virus 40 Large T‐Antigen Gene , 1991, Japanese journal of cancer research : Gann.

[192]  M. Westphal,et al.  Vasopressin in critical illness: sometimes even old players leave a lot to discover. Preface. , 2008, Best practice & research. Clinical anaesthesiology.

[193]  C. Ferris,et al.  Vasopressin/Serotonin Interactions in the Anterior Hypothalamus Control Aggressive Behavior in Golden Hamsters , 1997, The Journal of Neuroscience.

[194]  B. Altura Dose-response relationships for arginine vasopressin and synthetic analogs on three types of rat blood vessels: possible evidence for regional differences in vasopressin receptor sites within a mammal. , 1975, The Journal of pharmacology and experimental therapeutics.

[195]  T. Goodwin,et al.  The effect of the oxytocin antagonist atosiban on preterm uterine activity in the human. , 1994, American journal of obstetrics and gynecology.

[196]  M. Maggi,et al.  Potential use of oxytocin and vasopressin V1a antagonists in the treatment of preterm labour and primary dysmenorrhoea. , 1995, Advances in experimental medicine and biology.

[197]  J. Masri,et al.  Protein Kinase C Regulates Internal Initiation of Translation of the GATA-4 mRNA following Vasopressin-induced Hypertrophy of Cardiac Myocytes* , 2007, Journal of Biological Chemistry.

[198]  J. Du,et al.  All three vasopressin receptor sub-types are expressed by small-cell carcinoma. , 1998, Advances in experimental medicine and biology.

[199]  W. Young,et al.  Vasopressin: Behavioral roles of an “original” neuropeptide , 2008, Progress in Neurobiology.

[200]  B. Kobilka Structural insights into adrenergic receptor function and pharmacology. , 2011, Trends in pharmacological sciences.

[201]  G. Vinson,et al.  Oxytocin and arginine vasopressin stimulate steroid secretion by the isolated perfused rat adrenal gland , 1987, Neuropeptides.

[202]  C. Farquhar,et al.  Diagnosis and management of dysmenorrhoea , 2006, BMJ : British Medical Journal.

[203]  J. V. van Heerikhuize,et al.  Elevated serum oxytocin of the vasopressin-deficient Brattleboro rat is present throughout life and is not sensitive to treatment with vasopressin. , 1988, Acta endocrinologica.

[204]  C. Record,et al.  CONTROLLED TRIAL OF TERLIPRESSIN ('GLYPRESSIN') VERSUS VASOPRESSIN IN THE EARLY TREATMENT OF OESOPHAGEAL VARICES , 1982, The Lancet.

[205]  G. Robertson,et al.  Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. , 1973, The Journal of clinical investigation.

[206]  H. Gainer,et al.  Synthesis, transport, and release of posterior pituitary hormones. , 1980, Science.

[207]  I. Clarke,et al.  Neuroendocrine mechanisms of innate states of attenuated responsiveness of the hypothalamo-pituitary adrenal axis to stress , 2006, Frontiers in Neuroendocrinology.

[208]  H. Fujiki,et al.  Enhanced glucose tolerance in the Brattleboro rat. , 2011, Biochemical and biophysical research communications.

[209]  K. Maršál,et al.  The oxytocin antagonist atosiban versus the beta-agonist terbutaline in the treatment of preterm labor. A randomized, double-blind, controlled study. , 2001, Acta obstetricia et gynecologica Scandinavica.

[210]  T. Thrasher Baroreceptor Regulation of Vasopressin and Renin Secretion: Low-Pressure versus High-Pressure Receptors , 1994, Frontiers in Neuroendocrinology.

[211]  L. Albizu,et al.  Past, present and future of vasopressin and oxytocin receptor oligomers, prototypical GPCR models to study dimerization processes. , 2010, Current opinion in pharmacology.

[212]  W. Young,et al.  The hypothalamic-pituitary-adrenal axis response to stress in mice lacking functional vasopressin V1b receptors. , 2007, Endocrinology.

[213]  A. Cools,et al.  Prepulse inhibition and latent inhibition: the role of dopamine in the medial prefrontal cortex , 1996, Neuroscience.

[214]  E. Rozengurt,et al.  Vasopressin stimulation of mouse 3T3 cell growth. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[215]  K. Henderson,et al.  Vasopressin-induced vasoconstriction: two concentration-dependent signaling pathways. , 2007, Journal of applied physiology.

[216]  V. S. Bishop,et al.  Effect of vasopressin on baroreflex control of lumbar sympathetic nerve activity and hindquarter resistance. , 1996, The American journal of physiology.

[217]  K. Tomita,et al.  Physiological effects of vasopressin and atrial natriuretic peptide in the collecting duct. , 2001, Cardiovascular research.

[218]  Nancy L Pedersen,et al.  Genetic variation in the vasopressin receptor 1a gene (AVPR1A) associates with pair-bonding behavior in humans , 2008, Proceedings of the National Academy of Sciences.

[219]  S. Jordan,et al.  Intensive care in adults with congenital heart disease: cost implications of a changing patient population , 2005, Critical Care.

[220]  G. Gillies,et al.  Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin , 1982, Nature.

[221]  Eric Reiter,et al.  GRKs and β-arrestins: roles in receptor silencing, trafficking and signaling , 2006, Trends in Endocrinology & Metabolism.

[222]  M. Shibasaki,et al.  VASOPRESSIN STIMULATES THE PRODUCTION OF EXTRACELLULAR MATRIX BY CULTURED RAT MESANGIAL CELLS , 2008, Clinical and experimental pharmacology & physiology.

[223]  C. Barberis,et al.  Molecular cloning of the receptor for human antidiuretic hormone , 1992, Nature.

[224]  R. Dantzer,et al.  Modulation of social memory in male rats by neurohypophyseal peptides , 1987, Psychopharmacology.

[225]  T. Van Itallie,et al.  Glycogenolytic effect of vasopressin in the canine liver. , 1960, The American journal of physiology.

[226]  G. Tsujimoto,et al.  Vasopressin V1A receptor enhances baroreflex via the central component of the reflex arc. , 2007, European journal of pharmacology.

[227]  C. S. Gal,et al.  Vasopressin Does Not Mediate Hypersensitivity of the Hypothalamic Pituitary Adrenal Axis during Chronic Stress , 2008, Annals of the New York Academy of Sciences.

[228]  R. Hauger,et al.  Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets. , 2006, CNS & neurological disorders drug targets.

[229]  G. Tsujimoto,et al.  The vasopressin V1b receptor critically regulates hypothalamic-pituitary-adrenal axis activity under both stress and resting conditions. , 2004, The Journal of clinical investigation.

[230]  D. Rognan,et al.  Mapping the binding site of arginine vasopressin to V1a and V1b vasopressin receptors. , 2007, Molecular endocrinology.

[231]  M. Caron,et al.  Association of β-Arrestin with G Protein-coupled Receptors during Clathrin-mediated Endocytosis Dictates the Profile of Receptor Resensitization* , 1999, The Journal of Biological Chemistry.

[232]  K. Allan Pharmacological prevention of prematurity. , 2007 .

[233]  T. Insel,et al.  Oxytocin: who needs it? , 2001, Progress in Brain Research.

[234]  R. Derijk,et al.  Anxious–Retarded Depression: Relation with Plasma Vasopressin and Cortisol , 2003, Neuropsychopharmacology.

[235]  Claude D Martin,et al.  Clinical review: Vasopressin and terlipressin in septic shock patients , 2004, Critical care.

[236]  S. Hamburger,et al.  Cerebrospinal fluid neurochemistry in children and adolescents with obsessive-compulsive disorder. , 1992, Archives of general psychiatry.

[237]  T Machii,et al.  Acylcarnitine metabolism during fasting and after refeeding. , 1996, Biochemical and biophysical research communications.

[238]  M. Creager,et al.  Vasopressin-mediated forearm vasodilation in normal humans. Evidence for a vascular vasopressin V2 receptor. , 1989, The Journal of clinical investigation.

[239]  A. O'Carroll,et al.  The Vasopressin V1b Receptor Modulates Plasma Corticosterone Responses to Dehydration‐Induced Stress , 2011, Journal of neuroendocrinology.

[240]  C. Ferris,et al.  Patterns of brain vasopressin receptor distribution associated with social organization in microtine rodents , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[241]  D. Jezova,et al.  Signs of attenuated depression-like behavior in vasopressin deficient Brattleboro rats , 2007, Hormones and Behavior.

[242]  M. Kurachi,et al.  Subchronic phencyclidine administration alters central vasopressin receptor binding and social interaction in the rat , 2003, Brain Research.

[243]  Shizuka Murakami,et al.  PARTICIPATION OF VASOPRESSIN IN THE DEVELOPMENT OF CEREBRAL VASOSPASM IN A RAT MODEL OF SUBARACHNOID HAEMORRHAGE , 2004, Clinical and experimental pharmacology & physiology.

[244]  S. Lightman,et al.  Blockade of the V(1b) receptor reduces ACTH, but not corticosterone secretion induced by stress without affecting basal hypothalamic-pituitary-adrenal axis activity. , 2008, The Journal of endocrinology.

[245]  H. Sadeghi,et al.  Transient Phosphorylation of the V1a Vasopressin Receptor* , 1998, The Journal of Biological Chemistry.

[246]  J. Ruijter,et al.  Vasopressin increases GABAergic inhibition of rat hypothalamic paraventricular nucleus neurons in vitro. , 2000, Journal of neurophysiology.

[247]  Mario J. Borgnia,et al.  The Aquaporins, Blueprints for Cellular Plumbing Systems* , 1998, The Journal of Biological Chemistry.

[248]  W. Wernet,et al.  SSR149415, a non-peptide vasopressin V1b receptor antagonist, has long-lasting antidepressant effects in the olfactory bulbectomy-induced hyperactivity depression model , 2008, Naunyn-Schmiedeberg's Archives of Pharmacology.

[249]  R. Ramsay,et al.  Carnitine acyltransferases and their influence on CoA pools in health and disease. , 2004, Molecular aspects of medicine.

[250]  Y. Ishizuka,et al.  Involvement of vasopressin V1b receptor in anti-anxiety action of SSRI and SNRI in mice , 2010, Neuroscience Research.

[251]  G. Vassart,et al.  Non-peptide arginine-vasopressin antagonists: the vaptans , 2008, The Lancet.

[252]  J. Warberg,et al.  The role of vasopressin in acute cerebral vasospasm. Effect on spasm of a vasopressin antagonist or vasopressin antiserum. , 1988, Journal of neurosurgery.

[253]  G. Guillon,et al.  Molecular and functional characterization of V1b vasopressin receptor in rat adrenal medulla. , 1996, Endocrinology.

[254]  D. Overstreet,et al.  Antidepressant-like effects of the vasopressin V1b receptor antagonist SSR149415 in the Flinders Sensitive Line rat , 2005, Pharmacology Biochemistry and Behavior.

[255]  N. Altszuler,et al.  Effects of vasopressin on insulin secretion and inositol phosphate production in a hamster beta cell line (HIT). , 1990, Endocrinology.

[256]  R. Franceschini,et al.  Evaluation of the Secretory Pattern of Plasma Arginine Vasopressin in Stroke Patients , 2001, Cerebrovascular Diseases.

[257]  G. Ramsby,et al.  Intraarterial vasopressin in the treatment of upper gastrointestinal hemorrhage: a prospective, controlled clinical trial. , 1975, Gastroenterology.

[258]  G. Mazzocchi,et al.  Evidence that endogenous arginine-vasopressin (AVP) is involved in the maintenance of the growth and steroidogenic capacity of rat adrenal zona glomerulosa , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[259]  W. H. Howell THE PHYSIOLOGICAL EFFECTS OF EXTRACTS OF THE HYPOPHYSIS CEREBRI AND INFUNDIBULAR BODY , 1898, The Journal of experimental medicine.

[260]  M. Shoham,et al.  A molecular model of agonist and nonpeptide antagonist binding to the human V(1) vascular vasopressin receptor. , 2000, The Journal of pharmacology and experimental therapeutics.

[261]  W. Engeland,et al.  Neural circuitry in the regulation of adrenal corticosterone rhythmicity , 2005, Endocrine.

[262]  A. Tanoue,et al.  Alteration of glucose homeostasis in V1a vasopressin receptor-deficient mice. , 2007, Endocrinology.

[263]  R. Hauger,et al.  International Union of Pharmacology. XXXVI. Current Status of the Nomenclature for Receptors for Corticotropin-Releasing Factor and Their Ligands , 2003, Pharmacological Reviews.

[264]  K. Kikuchi,et al.  Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V(1A) receptor. , 2000, European journal of pharmacology.

[265]  J. Simms,et al.  Systematic analysis of the entire second extracellular loop of the V(1a) vasopressin receptor: key residues, conserved throughout a G-protein-coupled receptor family, identified. , 2007, The Journal of biological chemistry.

[266]  R. Acher,et al.  The Neurohypophysial Endocrine Regulatory Cascade: Precursors, Mediators, Receptors, and Effectors , 1995, Frontiers in Neuroendocrinology.

[267]  N. A. Popova,et al.  Reduced Walker 256 carcinosarcoma growth in vasopressin-deficient Brattleboro rats , 2010, Tumor Biology.

[268]  G. Griebel,et al.  Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[269]  G. Aguilera Corticotropin Releasing Hormone, Receptor Regulation and the Stress Response , 1998, Trends in Endocrinology & Metabolism.

[270]  M. Manning,et al.  Agonist selectivity in the oxytocin/vasopressin receptor family: new insights and challenges. , 2007, Biochemical Society transactions.

[271]  G. Nussdorfer,et al.  Arginin-vasopressin regulates proliferative activity of the regenerating rat adrenal cortex. , 2005, International Journal of Molecular Medicine.

[272]  R. Bridges,et al.  Arginine vasopressin V1a receptor antagonist impairs maternal memory in rats , 2008, Physiology & Behavior.

[273]  R. McIntyre,et al.  Discontinued psychiatric drugs in 2008 , 2009, Expert opinion on investigational drugs.

[274]  V. Wiegant,et al.  Plasma Levels of Arginine Vasopressin Elevated in Patients with Major Depression , 1997, Neuropsychopharmacology.

[275]  T. Durroux Principles: a model for the allosteric interactions between ligand binding sites within a dimeric GPCR. , 2005, Trends in pharmacological sciences.

[276]  E. Gould,et al.  Fatherhood affects dendritic spines and vasopressin V1a receptors in the primate prefrontal cortex , 2006, Nature Neuroscience.

[277]  W. Young,et al.  Attenuated Stress Response to Acute Lipopolysaccharide Challenge and Ethanol Administration in Vasopressin V1b Receptor Knockout Mice , 2007, Journal of neuroendocrinology.

[278]  Y. Arsenijévic,et al.  Vasopressin binding sites in the central nervous system: distribution and regulation. , 1998, Progress in brain research.

[279]  H. Marston,et al.  Characterization of a novel and selective V1B receptor antagonist. , 2008, Progress in brain research.

[280]  B. Mouillac,et al.  Oxytocin and vasopressin V1a and V2 receptors form constitutive homo- and heterodimers during biosynthesis. , 2003, Molecular endocrinology.

[281]  D. Devost,et al.  Identification of dimeric and oligomeric complexes of the human oxytocin receptor by co-immunoprecipitation and bioluminescence resonance energy transfer. , 2003, Journal of molecular endocrinology.

[282]  C. Johnston,et al.  Vasopressin in circulatory control and hypertension. , 1985, Journal of hypertension.

[283]  A. F. Muller,et al.  Vasopressin antagonists allow demonstration of a novel type of vasopressin receptor in the rat adenohypophysis. , 1986, Molecular pharmacology.

[284]  B. Walker Evidence for a vasodilatory effect of vasopressin in the conscious rat. , 1986, The American journal of physiology.

[285]  G. Drews,et al.  Mechanisms of the stimulation of insulin release by arginine-vasopressin in normal mouse islets. , 1990, The Journal of biological chemistry.

[286]  A. Náray-Fejes-Tóth,et al.  Minealocorticoid receptors and 11 beta-steroid dehydrogenase activity in renal principal and intercalated cells. , 1994, The American journal of physiology.

[287]  Y. Mori,et al.  Structure of the Rat V1a Vasopressin Receptor Gene and Characterization of Its Promoter Region and Complete cDNA Sequence of the 3′-End (*) , 1995, The Journal of Biological Chemistry.

[288]  D. Treit,et al.  Dissociation of the anxiolytic-like effects of Avpr1a and Avpr1b receptor antagonists in the dorsal and ventral hippocampus , 2008, Neuropeptides.

[289]  J. Nakano Cardiovascular actions of vasopressin. , 1973, Japanese circulation journal.

[290]  E. Tribollet,et al.  Vasopressin and oxytocin receptors in the central nervous system. , 1996, Critical reviews in neurobiology.

[291]  M. Burghammer,et al.  Crystal structure of the human β2 adrenergic G-protein-coupled receptor , 2007, Nature.

[292]  L. Albizu,et al.  Differential Coupling of the Vasopressin V1b Receptor through Compartmentalization within the Plasma Membrane , 2009, Molecular Pharmacology.

[293]  Allan E. Johnson,et al.  Localization and characterization of vasopressin binding sites in the rat brain using an iodinated linear AVP antagonist , 1993, Brain Research.

[294]  F. Endo,et al.  Hyperammonaemia in V1a vasopressin receptor knockout mice caused by the promoted proteolysis and reduced intrahepatic blood volume , 2007, The Journal of physiology.

[295]  D. Cabrol,et al.  Treatment of preterm labor with the oxytocin antagonist atosiban: a double-blind, randomized, controlled comparison with salbutamol. , 2001, European journal of obstetrics, gynecology, and reproductive biology.

[296]  J. Liard,et al.  Vasopressin in cardiovascular control: role of circulating vasopressin. , 1984, Clinical science.

[297]  I. Neumann,et al.  Vasopressin released within the central amygdala promotes maternal aggression , 2010, The European journal of neuroscience.

[298]  M. Kurachi,et al.  NC-1900, an arginine–vasopressin analogue, ameliorates social behavior deficits and hyperlocomotion in MK-801-treated rats: Therapeutic implications for schizophrenia , 2005, Brain Research.

[299]  P. Leung,et al.  Vasopressin rapidly stimulates phosphatidic acid‐phosphatidylinositol turnover in rat anterior pituitary cells , 1985, FEBS letters.

[300]  K. Davis,et al.  Dopamine in schizophrenia: a review and reconceptualization. , 1991, The American journal of psychiatry.

[301]  Michel Bouvier,et al.  Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. , 2005, Journal of the American Society of Nephrology : JASN.

[302]  B. McEwen General introduction to vasopressin and oxytocin: structure/metabolism, evolutionary aspects, neural pathway/receptor distribution, and functional aspects relevant to memory processing. , 2004, Advances in Pharmacology.

[303]  C. Ferris,et al.  Testosterone facilitates aggression by modulating vasopressin receptors in the hypothalamus , 1996, Physiology & Behavior.

[304]  A. Tanoue New topics in vasopressin receptors and approach to novel drugs: effects of vasopressin receptor on regulations of hormone secretion and metabolisms of glucose, fat, and protein. , 2009, Journal of pharmacological sciences.

[305]  A. Cowley,et al.  Role of vasopressin in cardiovascular regulation. , 1983, Federation proceedings.

[306]  J Hoflack,et al.  The Binding Site of Neuropeptide Vasopressin V1a Receptor , 1995, The Journal of Biological Chemistry.

[307]  P. Houillier,et al.  A role for Rhesus factor Rhcg in renal ammonium excretion and male fertility , 2008, Nature.

[308]  E. Ginns,et al.  Vasopressin V1b receptor knockout reduces aggressive behavior in male mice , 2002, Molecular Psychiatry.

[309]  P. L. Munson,et al.  Studies on the mechanism of stimulation of ACTH secretion with the aid of morphine as a blocking agent. , 1955, Endocrinology.

[310]  F. Endo,et al.  Hypermetabolism of fat in V1a vasopressin receptor knockout mice. , 2007, Molecular endocrinology.

[311]  C. Trandafir,et al.  Enhanced reactivity to vasopressin in rat basilar arteries during vasospasm after subarachnoid hemorrhage. , 2005, European journal of pharmacology.

[312]  M. Oz,et al.  Vasopressin pressor hypersensitivity in vasodilatory septic shock. , 1997, Critical care medicine.

[313]  R. Hodgson,et al.  Characterization of the V1a antagonist, JNJ-17308616, in rodent models of anxiety-like behavior , 2009, Psychopharmacology.

[314]  L. Filaretova,et al.  Age-dependent role of vasopressin in susceptibility of gastric mucosa to indomethacin-induced injury , 2010, Regulatory Peptides.

[315]  T. Laudański,et al.  The effect of relcovaptan (SR 49059), an orally active vasopressin V1a receptor antagonist, on uterine contractions in preterm labor , 2005, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[316]  G. Gillies,et al.  Corticotrophin releasing factor may be modulated vasopressin , 1979, Nature.

[317]  W. Russell,et al.  Vasopressin modulates liver regeneration in the Brattleboro rat. , 1983, The American journal of physiology.

[318]  W. Armstrong CHAPTER 15 – Hypothalamic Supraoptic and Paraventricular Nuclei , 2004 .

[319]  R. Dhar,et al.  A Bolus of Conivaptan Lowers Intracranial Pressure in a Patient with Hyponatremia after Traumatic Brain Injury , 2011, Neurocritical care.

[320]  W. Kuenzel,et al.  Heterooligomerization between vasotocin and corticotropin-releasing hormone (CRH) receptors augments CRH-stimulated 3',5'-cyclic adenosine monophosphate production. , 2007, Molecular endocrinology.

[321]  M. Bouvier,et al.  Receptor activity‐independent recruitment of βarrestin2 reveals specific signalling modes , 2004, The EMBO journal.

[322]  B. Dunning,et al.  Actions of neurohypophysial peptides on pancreatic hormone release. , 1984, The American journal of physiology.

[323]  H. Gutfreund,et al.  Enzyme kinetics , 1975, Nature.

[324]  Q. Pittman,et al.  Central effects of arginine vasopressin on blood pressure in rats. , 1982, Endocrinology.

[325]  W. Meyerhof,et al.  Mutational analysis and molecular modeling of the nonapeptide hormone binding domains of the [Arg8]vasotocin receptor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[326]  Meriem Semache,et al.  Lipolysis and the integrated physiology of lipid energy metabolism. , 2008, Molecular genetics and metabolism.

[327]  N. Tinel,et al.  Cell-surface protein-protein interaction analysis with time-resolved FRET and snap-tag technologies: application to GPCR oligomerization , 2008, Nature Methods.

[328]  T. Durroux,et al.  Pharmacology of Oxytocin and Vasopressin Receptors in the Central and Peripheral Nervous System a , 1992, Annals of the New York Academy of Sciences.

[329]  I. James,et al.  Intrauterine pressure, ischemia markers, and experienced pain during administration of a vasopressin V1a receptor antagonist in spontaneous and vasopressin‐induced dysmenorrhea , 2006, Acta obstetricia et gynecologica Scandinavica.

[330]  P. Petit,et al.  A Novel C-terminal Motif Is Necessary for the Export of the Vasopressin V1b/V3 Receptor to the Plasma Membrane* , 2005, Journal of Biological Chemistry.

[331]  L. Devi,et al.  Receptor heteromerization and drug discovery. , 2010, Trends in pharmacological sciences.

[332]  P. Casellas,et al.  Effect of a new, potent, non-peptide V1a vasopressin antagonist, SR 49059, on the binding and the mitogenic activity of vasopressin on Swiss 3T3 cells. , 1994, Biochemical pharmacology.

[333]  J Hoflack,et al.  Tyr115 is the key residue for determining agonist selectivity in the V1a vasopressin receptor. , 1995, The EMBO journal.

[334]  L. Agius,et al.  Effects of ciprofibrate and 2-[5-(4-chlorophenyl)pentyl]oxirane-2-carboxylate (POCA) on the distribution of carnitine and CoA and their acyl-esters and on enzyme activities in rats. Relation between hepatic carnitine concentration and carnitine acetyltransferase activity. , 1988, The Biochemical journal.

[335]  J. Javitch,et al.  Time-resolved FRET between GPCR ligands reveals oligomers in native tissues. , 2010, Nature chemical biology.

[336]  A. Marmarou,et al.  Modulation of AQP4 expression by the selective V1a receptor antagonist, SR49059, decreases trauma-induced brain edema. , 2008, Acta neurochirurgica. Supplement.

[337]  M. Imai,et al.  Electrophysiological study of luminal and basolateral vasopressin in rabbit cortical collecting duct. , 1995, The American journal of physiology.

[338]  P. Sullivan,et al.  Arginine Vasopressin Is Associated with Hypercortisolemia and Suicide Attempts in Depression , 1997, Biological Psychiatry.

[339]  Ruud M Buijs,et al.  Suprachiasmatic GABAergic Inputs to the Paraventricular Nucleus Control Plasma Glucose Concentrations in the Rat via Sympathetic Innervation of the Liver , 2004, The Journal of Neuroscience.

[340]  Tomohiko Mori,et al.  Downregulation of vasopressin V2 receptor promoter activity via V1a receptor pathway. , 2007, American journal of physiology. Renal physiology.

[341]  G. Griebel,et al.  Differential roles of amygdaloid nuclei in the anxiolytic- and antidepressant-like effects of the V1b receptor antagonist, SSR149415, in rats , 2006, Psychopharmacology.

[342]  R. Lamont,et al.  Critical appraisal and clinical utility of atosiban in the management of preterm labor , 2010, Therapeutics and clinical risk management.

[343]  B. Wiesner,et al.  A dileucine sequence and an upstream glutamate residue in the intracellular carboxyl terminus of the vasopressin V2 receptor are essential for cell surface transport in COS.M6 cells. , 1998, Molecular pharmacology.

[344]  G. Guillon,et al.  Vasopressin regulates adrenal functions by acting through different vasopressin receptor subtypes. , 1998, Advances in experimental medicine and biology.

[345]  Katherine J. Burton,et al.  Vasopressin receptor V1a regulates circadian rhythms of locomotor activity and expression of clock-controlled genes in the suprachiasmatic nuclei. , 2009, American journal of physiology. Regulatory, integrative and comparative physiology.

[346]  J. Granton,et al.  Science Review: Vasopressin and the cardiovascular system part 1 – receptor physiology , 2003, Critical care.

[347]  T. Nagasaka,et al.  Baroreflexive suppression of heat production and fall in body temperature following peripheral administration of vasopressin in rats. , 1984, The Japanese journal of physiology.

[348]  Christian Grillon,et al.  Gating and habituation of the startle reflex in schizophrenic patients. , 1992 .

[349]  G. Tsujimoto,et al.  Insulin hypersensitivity in mice lacking the V1b vasopressin receptor , 2007, The Journal of physiology.

[350]  P. Baylis,et al.  Plasma Arginine Vasopressin in diabetic ketoacidosis , 1979, Diabetologia.

[351]  N. Payet,et al.  Adrenal glomerulosa mitotic stimulation by posterior pituitary hormones , 1976, Cell and Tissue Research.

[352]  F. Marumo,et al.  Immunohistochemical localization of V2 vasopressin receptor along the nephron and functional role of luminal V2 receptor in terminal inner medullary collecting ducts. , 1995, The Journal of clinical investigation.

[353]  K. Groom Preterm labour. Pharmacological prevention of prematurity. , 2007, Best practice & research. Clinical obstetrics & gynaecology.

[354]  G. Guillon,et al.  Regulation of Adrenocortical Function by Vasopressin , 1998, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[355]  Nadia Ferguson-Myrthil Novel Agents for the Treatment of Hyponatremia: A Review of Conivaptan and Tolvaptan , 2010, Cardiology in review.

[356]  Richmond R. Thompson,et al.  Nonapeptide mechanisms of social cognition, behavior and species-specific social systems , 2010, Current Opinion in Neurobiology.

[357]  H. Gavras,et al.  Interaction of the Sympathetic Nervous System with Vasopressin and Renin in the Maintenance of Blood Pressure , 1982, Hypertension.

[358]  P. Raskin,et al.  Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.

[359]  S. Jard,et al.  Vasopressin: mechanisms of receptor activation. , 1983, Progress in brain research.

[360]  Y. Imai,et al.  Cardiovascular depression and stabilization by central vasopressin in rats. , 1990, HYPERTENSION.

[361]  Liping Wei,et al.  Adrenalectomy enhances the insulin sensitivity of muscle protein synthesis. , 2003, American journal of physiology. Endocrinology and metabolism.

[362]  U. Moll,et al.  The neuroendocrine thymus , 1988, Histochemistry.

[363]  G. Tsujimoto,et al.  Mutual regulation of vasopressin- and oxytocin-induced glucagon secretion in V1b vasopressin receptor knockout mice. , 2007, The Journal of endocrinology.

[364]  T. Insel,et al.  Increased affiliative response to vasopressin in mice expressing the V1a receptor from a monogamous vole , 1999, Nature.

[365]  T. Koshimizu,et al.  Vasopressin regulation of blood pressure and volume: findings from V1a receptor-deficient mice. , 2009, Kidney international.

[366]  L. Swanson,et al.  Immunohistochemical identification of neurons in the paraventricular nucleus of the hypothalamus that project to the medulla or to the spinal cord in the rat , 1982, The Journal of comparative neurology.

[367]  Mohamed H. Ahmed,et al.  Terlipressin and hepatorenal syndrome: what is important for nephrologists and hepatologists. , 2010, World journal of gastroenterology.

[368]  M. Shibasaki,et al.  Vasopressin increases type IV collagen production through the induction of transforming growth factor-beta secretion in rat mesangial cells. , 2008, Pharmacological research.

[369]  Sangeeta Mehta,et al.  Vasopressin versus norepinephrine infusion in patients with septic shock. , 2008, The New England journal of medicine.

[370]  O. Melander,et al.  Relation between human vasopressin 1a gene variance, fat intake, and diabetes. , 2009, The American journal of clinical nutrition.

[371]  Zoe R. Donaldson,et al.  Oxytocin, Vasopressin, and the Neurogenetics of Sociality , 2008, Science.

[372]  D. Bichet,et al.  Molecular biology of hereditary diabetes insipidus. , 2005, Journal of the American Society of Nephrology : JASN.

[373]  J. Hobbins,et al.  Maintenance treatment of preterm labor with the oxytocin antagonist atosiban. The Atosiban PTL-098 Study Group. , 2000, American journal of obstetrics and gynecology.

[374]  C. Ferris,et al.  Orally active vasopressin V1a receptor antagonist, SRX251, selectively blocks aggressive behavior , 2006, Pharmacology Biochemistry and Behavior.

[375]  J. Montani,et al.  Hemodynamic Effects of Exogenous and Endogenous Vasopressin at Low Plasma Concentrations in Conscious Dogs , 1980, Circulation research.

[376]  L. Young,et al.  Viral vector‐mediated gene transfer of the vole V1a vasopressin receptor in the rat septum: improved social discrimination and active social behaviour , 2003, The European journal of neuroscience.

[377]  Chien-Nan Lee,et al.  Randomized trial of oxytocin antagonist atosiban versus beta-adrenergic agonists in the treatment of spontaneous preterm labor in Taiwanese women. , 2009, Journal of the Formosan Medical Association = Taiwan yi zhi.

[378]  H. Gavras,et al.  Does vasopressin sustain blood pressure of normally hydrated healthy volunteers? , 1984, The American journal of physiology.

[379]  G. Schütz,et al.  Nucleotide sequence of cloned cDNA encoding bovine arginine vasopressin–neurophysin II precursor , 1982, Nature.

[380]  W. Young,et al.  Disruption of the vasopressin 1b receptor gene impairs the attack component of aggressive behavior in mice , 2007, Genes, brain, and behavior.

[381]  H. Nisell,et al.  Effectiveness and safety of the oxytocin antagonist atosiban versus beta‐adrenergic agonists in the treatment of preterm labour , 2003, BJOG : an international journal of obstetrics and gynaecology.

[382]  D. Devost,et al.  Homo‐ and Hetero‐Dimeric Complex Formations of the Human Oxytocin Receptor , 2004, Journal of neuroendocrinology.

[383]  G. Makara,et al.  Congenital vasopressin deficiency and acute and chronic opiate effects on hypothalamo-pituitary-adrenal axis activity in Brattleboro rats. , 2007, The Journal of endocrinology.

[384]  J. T. Shepherd,et al.  Vasopressin Causes Endothelium‐Dependent Relaxations of the Canine Basilar Artery , 1984, Circulation research.

[385]  W. Young,et al.  The vasopressin Avprlb receptor: Molecular and pharmacological studies , 2010, Stress.

[386]  C. Belzung,et al.  Involvement of vasopressin in affective disorders. , 2008, European journal of pharmacology.

[387]  J. B. Murray,et al.  Phencyclidine (PCP): A Dangerous Drug, but Useful in Schizophrenia Research , 2002, The Journal of psychology.

[388]  G. Griebel,et al.  An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders. , 2006, CNS drug reviews.

[389]  W. Young,et al.  Vasopressin 1a receptor knockout mice have a subtle olfactory deficit but normal aggression , 2007, Genes, brain, and behavior.

[390]  J. Clements,et al.  Arginine vasopressin (AVP) and AVP-like immunoreactivity in peripheral tissues. , 1986, Endocrine reviews.

[391]  G. Owens,et al.  Arginine Vasopressin‐Induced Hypertrophy of Cultured Rat Aortic Smooth Muscle Cells , 1989, Hypertension.

[392]  Gary Bornstein,et al.  Molecular genetic studies of the arginine vasopressin 1a receptor (AVPR1a) and the oxytocin receptor (OXTR) in human behaviour: from autism to altruism with some notes in between. , 2008, Progress in brain research.

[393]  R. Oishi,et al.  New topics in vasopressin receptors and approach to novel drugs: role of the vasopressin receptor in psychological and cognitive functions. , 2009, Journal of pharmacological sciences.

[394]  H. Akashi,et al.  Arginine vasopressin is an ideal drug after cardiac surgery for the management of low systemic vascular resistant hypotension concomitant with pulmonary hypertension. , 2007, Interactive cardiovascular and thoracic surgery.

[395]  M. Åkerlund,et al.  Inhibitory effects of SR 49059 on oxytocin‐and vasopressin‐induced uterine contractions in non‐pregnant women , 2004, Acta obstetricia et gynecologica Scandinavica.

[396]  M. Keck,et al.  Vasopressin in CSF and plasma in depressed suicide attempters: preliminary results , 2002, European Neuropsychopharmacology.

[397]  Manfred Burghammer,et al.  Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. , 2007, Nature.

[398]  G. Gimpl,et al.  The oxytocin receptor system: structure, function, and regulation. , 2001, Physiological reviews.

[399]  W. Vale,et al.  Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin , 1981 .

[400]  P. Pothier,et al.  On the presence of chromaffin cells in the adrenal cortex: their possible role in adrenocortical function. , 1987, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[401]  G. Tsujimoto,et al.  V1a vasopressin receptors maintain normal blood pressure by regulating circulating blood volume and baroreflex sensitivity , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[402]  S L Lightman,et al.  Emergence of an isolated arginine vasopressin (AVP) response to stress after repeated restraint: a study of both AVP and corticotropin-releasing hormone messenger ribonucleic acid (RNA) and heteronuclear RNA. , 1997, Endocrinology.

[403]  A. Yarkov,et al.  Arginine-vasopressin in nucleus of the tractus solitarius induces hyperglycemia and brain glucose retention , 2001, Brain Research.

[404]  D. Chassard,et al.  Effect of SR49059, an orally active V1a vasopressin receptor antagonist, in the prevention of dysmenorrhoea , 2000, BJOG : an international journal of obstetrics and gynaecology.

[405]  D. Swaab,et al.  Hypothalamic Vasopressin and Oxytocin mRNA Expression in Relation to Depressive State in Alzheimer’s Disease: A Difference With Major Depressive Disorder , 2009, Journal of neuroendocrinology.

[406]  P. Conn,et al.  G Protein-Coupled Receptor Trafficking in Health and Disease: Lessons Learned to Prepare for Therapeutic Mutant Rescue in Vivo , 2007, Pharmacological Reviews.

[407]  H. Vaudry,et al.  Vasopressin stimulates cortisol secretion from human adrenocortical tissue through activation of V1 receptors. , 1993, The Journal of clinical endocrinology and metabolism.

[408]  M. Birnbaumer Vasopressin Receptors , 2000, Trends in Endocrinology & Metabolism.

[409]  J. Kreisberg,et al.  Arginine vasopressin stimulates mesangial cell proliferation by activating the epidermal growth factor receptor. , 2001, American journal of physiology. Renal physiology.

[410]  P. Hamet,et al.  Ectopic and abnormal hormone receptors in adrenal Cushing's syndrome. , 2001, Endocrine reviews.

[411]  D. Rockey,et al.  Complications and outcomes in chronic liver disease , 2011, Current opinion in gastroenterology.

[412]  F. Marumo,et al.  Different localization and regulation of two types of vasopressin receptor messenger RNA in microdissected rat nephron segments using reverse transcription polymerase chain reaction. , 1993, The Journal of clinical investigation.

[413]  G. Griebel,et al.  Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist. , 2002, The Journal of pharmacology and experimental therapeutics.

[414]  E. Hasser,et al.  Reflex effect of vasopressin after blockade of V1 receptors in the area postrema. , 1990, Circulation research.

[415]  H. Vaudry,et al.  Evidence for a role of vasopressin in the control of aldosterone secretion in primary aldosteronism: in vitro and in vivo studies. , 2006, The Journal of clinical endocrinology and metabolism.

[416]  C. Haslett,et al.  Targeting V1A‐vasopressin receptors with [Arg6, D‐Trp7,9, NmePhe8]‐substance P (6‐11) identifies a strategy to develop novel anti‐cancer therapies , 2009, British journal of pharmacology.

[417]  Philippe Froguel,et al.  Disruption of Adiponectin Causes Insulin Resistance and Neointimal Formation* , 2002, The Journal of Biological Chemistry.

[418]  M. Craighead,et al.  Attenuated Stress Response to Acute Restraint and Forced Swimming Stress in Arginine Vasopressin 1b Receptor Subtype (Avpr1b) Receptor Knockout Mice and Wild-Type Mice Treated with a Novel Avpr1b Receptor Antagonist , 2010, Journal of neuroendocrinology.

[419]  Howard Eichenbaum,et al.  Vasopressin 1b Receptor Knock-Out Impairs Memory for Temporal Order , 2009, The Journal of Neuroscience.

[420]  E. Schiffrin,et al.  Abnormal adrenal and vascular responses to vasopressin mediated by a V1-vasopressin receptor in a patient with adrenocorticotropin-independent macronodular adrenal hyperplasia, Cushing's syndrome, and orthostatic hypotension. , 1997, The Journal of clinical endocrinology and metabolism.

[421]  A. Náray-Fejes-Tóth,et al.  Distribution of mineralocorticoid and glucocorticoid receptor mRNA along the nephron. , 1993, The American journal of physiology.

[422]  L. Branco,et al.  Role of L-glutamate in systemic AVP-induced hypothermia. , 2003, Journal of applied physiology.

[423]  Xueqian Zhang,et al.  Controlled and cardiac-restricted overexpression of the arginine vasopressin V1A receptor causes reversible left ventricular dysfunction through Gαq-mediated cell signaling. , 2011, Circulation.

[424]  G. Griebel,et al.  AVP V1b selective antagonist SSR149415 blocks aggressive behaviors in hamsters , 2005, Pharmacology Biochemistry and Behavior.

[425]  H. Vaudry,et al.  Vasopressin-responsive adrenocortical tumor in a mild Cushing's syndrome: in vivo and in vitro studies. , 1995, The Journal of clinical endocrinology and metabolism.

[426]  W. Maier,et al.  Combined effects of exonic polymorphisms in CRHR1 and AVPR1B genes in a case/control study for panic disorder , 2008, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[427]  C. S. Gal,et al.  Key amino acids located within the transmembrane domains 5 and 7 account for the pharmacological specificity of the human V1b vasopressin receptor. , 2004, Molecular endocrinology.

[428]  F. Marumo,et al.  Role of urinary arginine vasopressin in the sodium excretion in patients with chronic renal failure. , 1996, The American journal of the medical sciences.

[429]  R. Arban V1b receptors: new probes for therapy. , 2007, Endocrinology.

[430]  I. Bird,et al.  Vasopressin stimulates cortisol secretion and phosphoinositide catabolism in cultured bovine adrenal fasciculata/reticularis cells. , 1990, Journal of Molecular Endocrinology.

[431]  C. Hoppel,et al.  Relationship between acid-soluble carnitine and coenzyme A pools in vivo. , 1980, The Biochemical journal.

[432]  S. Gardiner,et al.  Differential Cardiovascular Effects of Centrally Administered Vasopressin in Conscious Long Evans and Brattleboro Rats , 1989, Circulation research.

[433]  W. Oelkers,et al.  Effects of incremental infusions of arginine vasopressin on adrenocorticotropin and cortisol secretion in man. , 1988, The Journal of clinical endocrinology and metabolism.

[434]  H. Westphal,et al.  Vasopressin receptor 1a-mediated negative regulation of B cell receptor signaling , 2003, Journal of Neuroimmunology.

[435]  C. Adler,et al.  Effects of Acute Metabolic Stress on the Peripheral Vasopressinergic System in Schizophrenia , 2003, Journal of psychopharmacology.

[436]  L. Bankir,et al.  Sodium excretion in response to vasopressin and selective vasopressin receptor antagonists. , 2008, Journal of the American Society of Nephrology : JASN.

[437]  Shuyi Wang,et al.  Vasopressin promotes cardiomyocyte hypertrophy via the vasopressin V1A receptor in neonatal mice. , 2007, European journal of pharmacology.

[438]  M. Åkerlund Involvement of oxytocin and vasopressin in the pathophysiology of preterm labor and primary dysmenorrhea. , 2002, Progress in brain research.

[439]  A. Tanoue,et al.  Impaired arginine-vasopressin-induced aldosterone release from adrenal gland cells in mice lacking the vasopressin V1A receptor. , 2007, European journal of pharmacology.

[440]  S. Sasaki,et al.  Aquaporins in kidney pathophysiology , 2010, Nature Reviews Nephrology.

[441]  P. Shilling,et al.  Reversal of Sensorimotor Gating Deficits in Brattleboro Rats by Acute Administration of Clozapine and a Neurotensin Agonist, but not Haloperidol: a Potential Predictive Model for Novel Antipsychotic Effects , 2004, Neuropsychopharmacology.

[442]  S. Ferguson,et al.  Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. , 2001, Pharmacological reviews.

[443]  S. Alexander,et al.  Effect of insulin-induced hypoglycaemia on secretion patterns and rates of corticotrophin-releasing hormone, arginine vasopressin and adrenocorticotrophin in horses. , 1997, The Journal of endocrinology.

[444]  M. Thibonnier,et al.  Molecular pharmacology of human vasopressin receptors. , 1998, Advances in experimental medicine and biology.

[445]  C. Kirk,et al.  Rapid stimulation, by vasopressin and adrenaline, of inorganic phosphate incorporation into phosphatidyl inositol in isolated hepatocytes , 1977, FEBS letters.

[446]  S. Subburaju,et al.  The parvocellular vasopressinergic system and responsiveness of the hypothalamic pituitary adrenal axis during chronic stress. , 2008, Progress in brain research.

[447]  G. Alonso,et al.  Hypothalamic vasopressin release and hepatocyte Ca2+ signaling during liver regeneration: an interplay stimulating liver growth and bile flow , 2003 .

[448]  S. Hawtin Pharmacological Chaperone Activity of SR49059 to Functionally Recover Misfolded Mutations of the Vasopressin V1a Receptor* , 2006, Journal of Biological Chemistry.

[449]  E. Rozengurt,et al.  Phorbol esters and vasopressin stimulate DNA synthesis by a common mechanism , 1980, Nature.

[450]  M. Knepper,et al.  Control of sodium and potassium transport in the cortical collecting duct of the rat. Effects of bradykinin, vasopressin, and deoxycorticosterone. , 1985, The Journal of clinical investigation.

[451]  B. Leventhal,et al.  Transmission disequilibrium testing of arginine vasopressin receptor 1A (AVPR1A) polymorphisms in autism , 2002, Molecular Psychiatry.

[452]  M. Bouvier,et al.  Roles of G‐protein‐coupled receptor dimerization , 2004, EMBO reports.

[453]  S. Lightman,et al.  Effect of vasopressin 1b receptor blockade on the hypothalamic-pituitary-adrenal response of chronically stressed rats to a heterotypic stressor. , 2008, The Journal of endocrinology.

[454]  Larry J Young,et al.  Profound Impairment in Social Recognition and Reduction in Anxiety-Like Behavior in Vasopressin V1a Receptor Knockout Mice , 2004, Neuropsychopharmacology.

[455]  M. Joubert,et al.  Aberrant adrenal sensitivity to vasopressin in adrenal tumours associated with subclinical or overt autonomous hypercortisolism: is this explained by an overexpression of vasopressin receptors? , 2008, Clinical endocrinology.

[456]  H. D. de Wardener The hypothalamus and hypertension. , 2001, Physiological reviews.

[457]  R. Bridges,et al.  Central actions of arginine vasopressin and a V1a receptor antagonist on maternal aggression, maternal behavior, and grooming in lactating rats , 2008, Pharmacology Biochemistry and Behavior.

[458]  W. Hsu,et al.  Effect of AVP and oxytocin on insulin release: involvement of V1b receptors. , 1995, The American journal of physiology.

[459]  Young Vr,et al.  Ntau-methylhistidine (3-methylhistidine) and muscle protein turnover: an overview. , 1978 .

[460]  J. Elands,et al.  Oxytocin-stimulated release of adrenocorticotropin from the rat pituitary is mediated by arginine vasopressin receptors of the V1b type. , 1994, Endocrinology.

[461]  C. Tortorella,et al.  Arginine-Vasopressin Stimulates CRH and ACTH Release by Rat Adrenal Medulla, Acting Via the V1 Receptor Subtype and a Protein Kinase C-Dependent Pathway , 1997, Peptides.

[462]  M. Altemus,et al.  Chronic fluoxetine treatment reduces hypothalamic vasopressin secretion in vitro , 1992, Brain Research.

[463]  N. Dulin,et al.  The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways. , 1997, Endocrinology.

[464]  G. Nussdorfer,et al.  In-vitro and in-vivo studies of the effects of arginine-vasopressin on the secretion and growth of rat adrenal cortex. , 1995, Histology and histopathology.

[465]  C. Azuma,et al.  Molecular characterization of a cloned human oxytocin receptor. , 1994, European journal of endocrinology.

[466]  K. Longo,et al.  Expression of all known vasopressin receptor subtypes by small cell tumors implies a multifaceted role for this neuropeptide. , 1998, Cancer research.

[467]  Mark J. Zylka,et al.  A Molecular Mechanism Regulating Rhythmic Output from the Suprachiasmatic Circadian Clock , 1999, Cell.

[468]  H. Albers,et al.  Arginine‐vasopressin and the regulation of aggression in female Syrian hamsters (Mesocricetus auratus) , 2010, The European journal of neuroscience.

[469]  S. Reppert,et al.  Vasopressin exhibits a rhythmic daily pattern in cerebrospinal fluid but not in blood. , 1981, Science.

[470]  B. Dunning,et al.  Modulation of insulin and glucagon secretion from the perfused rat pancreas by the neurohypophysial hormones and by desamino-D-arginine vasopressin (DDAVP) , 1984, Peptides.

[471]  R. Ravid,et al.  Localisation of oxytocin, vasopressin and parts of precursors in the human neonatal adrenal , 2004, Histochemistry.

[472]  V. Boulay,et al.  V1b and CRHR1 receptor heterodimerization mediates synergistic biological actions of vasopressin and CRH. , 2012, Molecular endocrinology.

[473]  Tomoaki Tanaka,et al.  A possible association between aldosterone response to vasopressin and circadian change of aldosterone in the patients with aldosterone-producing adenoma , 2008, Peptides.

[474]  Tao Yang,et al.  Effects of Nonpeptide V1 Vasopressin Receptor Antagonist SR-49059 on Infarction Volume and Recovery of Function in a Focal Embolic Stroke Model , 2002, Stroke.

[475]  G. Griebel,et al.  Functional and pharmacological characterization of the first specific agonist and antagonist for the V1b receptor in mammals. , 2003, Stress.

[476]  J. Peters,et al.  The Vasopressin System: Physiology and Clinical Strategies , 2006, Anesthesiology.

[477]  D. Jezova,et al.  Repeated stress-induced activation of corticotropin-releasing factor neurons enhances vasopressin stores and colocalization with corticotropin-releasing factor in the median eminence of rats. , 1991, Neuroendocrinology.

[478]  S. Phelps,et al.  Variation in neural V1aR predicts sexual fidelity and space use among male prairie voles in semi-natural settings , 2008, Proceedings of the National Academy of Sciences.

[479]  R. Star,et al.  Intranephron localization and regulation of the V1a vasopressin receptor during chronic metabolic acidosis and dehydration in rats , 2001, Pflügers Archiv.

[480]  J. Gádoros,et al.  Evidence of an association between the vasopressin V1b receptor gene (AVPR1B) and childhood-onset mood disorders. , 2007, Archives of general psychiatry.

[481]  R. Kahn,et al.  Selective impairments in the stress response in schizophrenic patients , 2000, Psychopharmacology.

[482]  L. Rodrigues,et al.  The influence of vasopressin and related peptides on glycogen phosphorylase activity and phosphatidylinositol metabolism in hepatocytes. , 1979, The Biochemical journal.

[483]  O. Manzoni,et al.  Vasopressin stimulates steroid secretion in human adrenal glands: comparison with angiotensin-II effect. , 1995, Endocrinology.

[484]  D. Cook,et al.  Intracellular ATP directly blocks K+ channels in pancreatic B-cells , 1984, Nature.

[485]  I. Neumann,et al.  Brain vasopressin is an important regulator of maternal behavior independent of dams' trait anxiety , 2008, Proceedings of the National Academy of Sciences.

[486]  F. Morel,et al.  Vasopressin dependent adenylate cyclase in single segments of rabbit kidney tubule , 1975, Pflügers Archiv.

[487]  C. S. Gal,et al.  The Discovery of Novel Vasopressin V1b Receptor Ligands for Pharmacological, Functional and Structural Investigations , 2004, Journal of neuroendocrinology.

[488]  G. J. de Vries,et al.  Vasopressin innervation of the mouse (Mus musculus) brain and spinal cord , 2011, The Journal of comparative neurology.

[489]  Michel Bouvier,et al.  Oligomerization of G-protein-coupled transmitter receptors , 2001, Nature Reviews Neuroscience.

[490]  A. Rofe,et al.  Metabolic effects of vasopressin infusion in the starved rat. Reversal of ketonaemia. , 1983, The Biochemical journal.

[491]  F. Ciruela,et al.  G‐protein‐coupled receptor heteromers: function and ligand pharmacology , 2008, British journal of pharmacology.

[492]  George Paxinos,et al.  The Mouse Brain in Stereotaxic Coordinates , 2001 .

[493]  Michel Bouvier,et al.  Heterodimerization of V1a and V2 vasopressin receptors determines the interaction with beta-arrestin and their trafficking patterns. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[494]  G. Aguilera,et al.  Vasopressinergic regulation of the hypothalamic–pituitary–adrenal axis: implications for stress adaptation , 2000, Regulatory Peptides.

[495]  H. Bruining,et al.  Vasopressin deficiency contributes to the vasodilation of septic shock. , 1998, Circulation.

[496]  K. Furuichi,et al.  Evidence that atypical vasopressin V(2) receptor in inner medulla of kidney is V(1B) receptor. , 2000, European journal of pharmacology.

[497]  Jerrold S. Meyer,et al.  Principles of Neuropsychopharmacology , 1997 .

[498]  Michael J. Brownstein,et al.  Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus , 1992, Nature.

[499]  J. Lehoux,et al.  Vasopressin: a potent growth factor in adrenal glomerulosa cells in culture. , 1984, Journal of steroid biochemistry.

[500]  H. Munro,et al.  Ntau-methylhistidine (3-methylhistidine) and muscle protein turnover: an overview. , 1978, Federation proceedings.

[501]  A. Guyton,et al.  Interaction of Vasopressin and the Baroreceptor Reflex System in the Regulation of Arterial Blood Pressure in the Dog , 1974, Circulation research.

[502]  G. Griebel,et al.  The corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, prevent stress-induced cognitive impairment in mice , 2011, Pharmacology Biochemistry and Behavior.

[503]  R. Rosenfeld Nature , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[504]  G. Guillon,et al.  Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. , 2008, Progress in brain research.

[505]  W. Ruwe,et al.  Thermoregulatory actions of centrally-administered vasopressin in the rat , 1986, Neuropharmacology.

[506]  A. Marmarou,et al.  Protective effect of the V1a receptor antagonist SR49059 on brain edema formation following middle cerebral artery occlusion in the rat. , 2006, Acta neurochirurgica. Supplement.

[507]  M. Shoham,et al.  Molecular pharmacology and modeling of vasopressin receptors. , 2002, Progress in brain research.

[508]  R. Landgraf,et al.  Maternal Behaviour is Associated with Vasopressin Release in the Medial Preoptic Area and Bed Nucleus of the Stria Terminalis in the Rat , 2010, Journal of neuroendocrinology.

[509]  H. Sitter,et al.  A comparison of vasopressin and epinephrine for out-of-hospital cardiopulmonary resuscitation. , 2004, The New England journal of medicine.

[510]  Eric Reiter,et al.  GRKs and beta-arrestins: roles in receptor silencing, trafficking and signaling. , 2006, Trends in endocrinology and metabolism: TEM.

[511]  C. Carter,et al.  Sex differences in oxytocin and vasopressin: Implications for autism spectrum disorders? , 2007, Behavioural Brain Research.

[512]  D. Dluzen,et al.  Olfactory bulb norepinephrine depletion abolishes vasopressin and oxytocin preservation of social recognition responses in rats , 1998, Neuroscience Letters.

[513]  Geenen,et al.  Review Article Thymic Expression of Neuroendocrine Self‐Peptide Precursors: Role in T Cell Survival and Self‐Tolerance , 1998, Journal of neuroendocrinology.

[514]  G. Makara,et al.  Glutamate agonists activate the hypothalamic–pituitary–adrenal axis through hypothalamic paraventricular nucleus but not through vasopressinerg neurons , 2005, Brain Research.

[515]  G. Tsujimoto,et al.  Effects of vasopressin V1b receptor deficiency on adrenocorticotropin release from anterior pituitary cells in response to oxytocin stimulation. , 2008, Endocrinology.

[516]  K. Tomita,et al.  Low pH stimulates vasopressin V2 receptor promoter activity and enhances downregulation induced by V1a receptor stimulation. , 2009, American journal of physiology. Renal physiology.

[517]  A. Tanoue,et al.  Enhanced effect of neuropeptide Y on food intake caused by blockade of the V(1A) vasopressin receptor. , 2009, European journal of pharmacology.

[518]  M. Brownstein,et al.  Molecular Biology of Vasopressin Receptors , 1995, Annals of the New York Academy of Sciences.

[519]  S. Israel,et al.  Association between arginine vasopressin 1a receptor (AVPR1a) promoter region polymorphisms and prepulse inhibition , 2009, Psychoneuroendocrinology.

[520]  E. D. de Kloet,et al.  Oxytocin receptors in the rat thymic gland. , 1988, European journal of pharmacology.

[521]  Keshava Rajagopal,et al.  Teaching old receptors new tricks: biasing seven-transmembrane receptors , 2010, Nature Reviews Drug Discovery.

[522]  C. S. Gal,et al.  Non-peptide vasopressin V1b receptor antagonists as potential drugs for the treatment of stress-related disorders. , 2005, Current pharmaceutical design.

[523]  B. Ahrén,et al.  G-protein-coupled receptors and islet function-implications for treatment of type 2 diabetes. , 2007, Pharmacology & therapeutics.

[524]  A. Austin,et al.  Vasopressin in liver disease--should we turn on or off? , 2008, Current clinical pharmacology.

[525]  Y. Oiso,et al.  Osmoregulation of Plasma Vasopressin in Diabetes Mellitus with Sustained Hyperglycemia , 1996, Journal of neuroendocrinology.

[526]  M. Oz,et al.  Vasopressin deficiency contributes to the vasodilation of septic shock. , 1997, Circulation.

[527]  Larry J. Young,et al.  Enhanced partner preference in a promiscuous species by manipulating the expression of a single gene , 2004, Nature.

[528]  C. S. Gal,et al.  The vasopressin V1b receptor as a therapeutic target in stress-related disorders. , 2003, Current drug targets. CNS and neurological disorders.

[529]  K. Mori,et al.  Structure and expression of a human oxytocin receptor , 1992, Nature.

[530]  N. Swerdlow,et al.  Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges , 2001, Psychopharmacology.

[531]  T. Laudański,et al.  Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women , 1999, British journal of obstetrics and gynaecology.

[532]  A. Takeshita,et al.  Biphasic forearm vascular responses to intraarterial arginine vasopressin. , 1989, The Journal of clinical investigation.

[533]  C. Kamei,et al.  Effects of metabolic fragments of [Arg8]-vasopressin on nerve growth in cultured hippocampal neurons , 2000, Brain Research Bulletin.

[534]  C. Broekkamp,et al.  Major tranquillizers can be distinguished from minor tranquillizers on the basis of effects on marble burying and swim-induced grooming in mice. , 1986, European journal of pharmacology.

[535]  A. Baertschi,et al.  A novel type of vasopressin receptor on anterior pituitary corticotrophs? , 1985, Endocrinology.

[536]  L. Albizu,et al.  Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands. , 2007, Journal of medicinal chemistry.

[537]  G. Aguilera,et al.  Dimerization Between Vasopressin V1b and Corticotropin Releasing Hormone Type 1 Receptors , 2007, Cellular and Molecular Neurobiology.

[538]  A. F. Muller,et al.  Properties of rat anterior pituitary vasopressin receptors: relation to adenylate cyclase and the effect of corticotropin-releasing factor. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[539]  D. Feifel,et al.  Vasopressin-deficient rats exhibit sensorimotor gating deficits that are reversed by subchronic haloperidol , 2001, Biological Psychiatry.